Despite the controversy that
Subscriber content
?
Subscriber content comes from Gigaom Research, bridging the gap between breaking news and long-tail research. Visit any of our reports to learn more and subscribe.
Advertisement
Advertisement
Advertisement
["wijax_41975e75f57ad9864694ce993fd67829","wijax_abd1271096b26a2eefadc149d85b4dee"]
{"source":"https:\/\/gigaom.com\/2008\/07\/17\/419-bt-steaming-ahead-with-phorm-trials\/wijax\/49e8740702c6da9341d50357217fb629","varname":"wijax_5849ed4fe602cae5e6d241e95fc3ab11","title_element":"header","title_class":"widget-title","title_before":"%3Cheader%20class%3D%22widget-title%22%3E","title_after":"%3C%2Fheader%3E"}
{"source":"https:\/\/gigaom.com\/2008\/07\/17\/419-bt-steaming-ahead-with-phorm-trials\/wijax\/49e8740702c6da9341d50357217fb629","varname":"wijax_5849ed4fe602cae5e6d241e95fc3ab11","title_element":"header","title_class":"widget-title","title_before":"%3Cheader%20class%3D%22widget-title%22%3E","title_after":"%3C%2Fheader%3E"}
Comments have been disabled for this post